Seek Returns

BIIB vs. EXEL: Biogen vs. Exelixis Stock Comparison

How do Biogen (BIIB) and Exelixis (EXEL) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Biogen (BIIB) and Exelixis (EXEL) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Biogen (BIIB) and Exelixis (EXEL)
Profile ItemBIIBEXEL
NameBiogen Inc.Exelixis Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization36.71 billion USD16.98 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateSeptember 17, 1991April 17, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIIB
EXEL
GSPC
Loading price history…
Biogen (BIIB) vs. Exelixis (EXEL), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Biogen (BIIB) and Exelixis (EXEL). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Biogen (BIIB) and Exelixis (EXEL). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Biogen (BIIB) and Exelixis (EXEL)
MetricBIIBEXEL
Total Return (1Y)65.44%74.98%
Total Return (3Y, Annualized)4.62%50.33%
Total Return (5Y, Annualized)-0.96%31.10%

Risk Profile

Drawdown History

BIIB
EXEL
GSPC
Loading price history…
Biogen (BIIB) vs. Exelixis (EXEL), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Biogen (BIIB) and Exelixis (EXEL). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Biogen (BIIB) and Exelixis (EXEL)
MetricBIIBEXEL
Volatility (1Y, Annualized)34.58%34.17%
Beta (5Y)0.080.41
Max Drawdown (5Y)-64.35%-35.41%
Avg. Volume (3M)1.05M2.33M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIIB and EXEL are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Biogen (BIIB) and Exelixis (EXEL)
MetricBIIBEXEL
Sharpe Ratio (1Y)1.772.07
Sortino Ratio (1Y)2.773.23

Profitability

ROE (TTM)

Exelixis (EXEL) at 44.32% sits in the top ROE quartile, while Biogen (BIIB) at 1.87% is closer to the peer norm — stronger capital efficiency for EXEL.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max
109.18%
Q3
6.23%
BIIB
1.87%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max
109.18%
EXEL
44.32%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Exelixis (EXEL) at 35.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Biogen (BIIB) at 3.38% keeps roughly the typical share for its industry.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max
18.05%
Q3
4.78%
BIIB
3.38%
Median
0.00%
Q1
-4.14%
Min
-17.05%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL
35.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Biogen (BIIB) at 24.12% and Exelixis (EXEL) at 40.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max
83.12%
BIIB
24.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max
83.12%
EXEL
40.75%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Biogen (BIIB) and Exelixis (EXEL)
MetricBIIBEXEL
ROE (TTM)1.87%44.32%
ROA (TTM)4.94%23.52%
Net Margin (TTM)3.38%35.45%
Operating Margin (TTM)24.12%40.75%
Gross Margin (TTM)75.77%96.26%

Growth

Revenue Growth

Both Biogen (BIIB) at 2.22% and Exelixis (EXEL) at 6.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Biogen (BIIB) at -21.38% and Exelixis (EXEL) at 57.95% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Biogen (BIIB) and Exelixis (EXEL)
MetricBIIBEXEL
Revenue Growth (YoY)2.22%6.98%
Revenue Growth (3Y CAGR)-0.94%12.93%
EPS Growth (YoY)-21.38%57.95%
EPS Growth (3Y CAGR)-25.04%70.59%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Biogen (BIIB) at 1.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BIIB.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BIIB
1.95
Min
0.10

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max
25.13
Q3
12.13
Median
5.52
EXEL
3.21
Q1
2.47
Min
0.10
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Biogen (BIIB) at 0.41 and Exelixis (EXEL) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max
1.42
Q3
0.65
BIIB
0.41
Median
0.15
Q1
0.02
Min
0.00

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
EXEL
0.09
Q1
0.02
Min
0.00
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Biogen (BIIB) and Exelixis (EXEL)
MetricBIIBEXEL
Current Ratio (MRQ)1.953.21
Debt / Equity (MRQ)0.410.09
Net Debt / EBITDA1.97-0.71

Dividends

Dividend Yield (TTM)

Neither Biogen (BIIB) nor Exelixis (EXEL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Biogen (BIIB) nor Exelixis (EXEL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Biogen (BIIB) and Exelixis (EXEL)
MetricBIIBEXEL
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB
107.51
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max
85.34
Q3
43.46
Median
26.69
EXEL
20.83
Q1
13.30
Min
0.07
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Biogen (BIIB) at 3.57 and Exelixis (EXEL) at 6.80 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max
58.18
Q3
25.77
Median
7.30
BIIB
3.57
Q1
3.01
Min
0.01

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max
58.18
Q3
25.77
Median
7.30
EXEL
6.80
Q1
3.01
Min
0.01
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Biogen (BIIB) at 1.94 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max
13.53
Q3
6.54
Median
3.25
BIIB
1.94
Q1
1.69
Min
-5.59

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max
13.53
EXEL
9.28
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Biogen (BIIB) vs. Exelixis (EXEL): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Biogen (BIIB) and Exelixis (EXEL)
MetricBIIBEXEL
P/E Ratio (TTM)107.5120.83
P/S Ratio (TTM)3.576.80
P/B Ratio (MRQ)1.949.28
Free Cash Flow Yield (TTM)2.20%4.47%